Venous Reflux Clinical Trial
Official title:
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early & Advanced Stage Superficial Venous Disease
Verified date | May 2024 |
Source | Medtronic Endovascular |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease
Status | Active, not recruiting |
Enrollment | 506 |
Est. completion date | April 30, 2028 |
Est. primary completion date | June 27, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient is =18 years of age 2. Patient has venous reflux in superficial truncal vein(s) (e.g., GSV, SSV, accessory saphenous veins) with CEAP 2 (symptomatic) or CEAP 3, 4a, 4b, 5, 6, appropriate for treatment, as confirmed by DUS 3. Eligibility for treatment: - VenaSeal vs ETA Study: Patient is eligible for treatment with the VenaSeal™ system and ETA - VenaSeal vs Surgical Stripping Study: Patient is eligible for treatment with the VenaSeal™ system and surgical stripping - VLU Study: patients should be eligible for treatment with the VenaSeal™ system 4. Treatable refluxing segment of target vein(s) 10 cm in length or longer 5. Patient has a target vein diameter of =3 mm throughout the intended treated segment of the target vein as measured by DUS while patient is standing 6. Patient is willing and capable of complying with specified follow-up evaluations at the specified times 7. Patient has an ability to understand the requirements of the study and to provide informed consent Exclusion Criteria: 1. Patient has a known history of allergic sensitivities (including but not limited to cyanoacrylate adhesives), or any other condition, which in the opinion of the investigator may make the patient more susceptible to cyanoacrylate adhesive hypersensitivity 2. Patient has known deep vein obstruction in the target limb, as identified by the site's standard of care 3. Patient has abnormal pulse exam or ABI <0.8 4. Patient has acute superficial thrombophlebitis 5. Patient requires any non-target vein treatments in the contralateral or ipsilateral limb, or any other surgical procedure up tp 30 days pre-procedure and through 3 months post-procedure 6. Patient has any co-morbid conditions, which in the investigator's opinion may interfere with the patient's compliance with study visits and procedures, or may confound interpretation of study data (e.g., congestive heart failure Class III and IV, non-ambulatory patients, severe hepatic dysfunction, life expectancy < 1 year) 7. IFU contraindications: - VenaSeal vs. ETA Study: Patient has VenaSeal™ system and/or ETA product's IFU contraindication(s) - VenaSeal vs Surgical Stripping Study: Patient has surgical stripping and/or VenaSeal™ system IFU contraindication(s) - VLU Study: Patient has VenaSeal™ system IFU contraindication(s) 8. Patient is non-ambulatory 9. Patient is a female of childbearing potential who may be pregnant or breastfeeding at the time of the index procedure 10. Patient belongs to a vulnerable population per investigator's judgment or patient has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures 11. Patient is currently participating in an investigational drug or device study when the data collected could be conflicting or biased due to participation in another study 12. Patient has documented COVID-19 infection currently or within the past 3 months. Patient is not completely recovered from past COVID-19 infection, per physician's discretion. 13. VLU Study: Patient has target ulceration identified to be of non-venous etiology, as confirmed by the independent core laboratory 14. VLU Study: Patient has target circumferential ulceration that cannot be captured in a single photograph (any ulcer curvature around the leg that goes out of sight) |
Country | Name | City | State |
---|---|---|---|
Australia | Sunshine Coast University Hospital | Birtinya | |
Australia | Wollongong Hospital | Wollongong | |
Canada | East Toronto Vascular Clinic | Toronto | Ontario |
France | CHU Dijon Bourgogne | Dijon | DIjon Cedex |
France | Clinique du Parc | Lyon | |
France | Clinique Pasteur | Toulouse | |
Germany | Praxis fur Innere Medizin und Gefäßkrankheiten | Halle | |
Italy | Ospedale Fatebenefratelli e Oftalmico | Milano | |
Italy | Azienda Ospedaliera di Padova Ospendale Sant' Antonio | Padova | |
Korea, Republic of | Gangnam Severance Hospital | Seoul | |
Korea, Republic of | Konkuk University Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Seoul Saint Mary's Hospital | Seoul | |
Netherlands | Rijnstate - Locatie Arnhem | Arnhem | |
Spain | Complejo Hospitalario Universitario Granada (Hospital Campus de la Salud) | Granada | |
Spain | Sanitas Hospital Universitario La Zarzuela | Madrid | |
United Kingdom | Bedfordshire Hospitals NHS Foundation Trust | Bedford | |
United Kingdom | Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital | Cambridge | |
United Kingdom | West London Vascular and Interventional Centre | Harrow | |
United Kingdom | Imperial College Healthcare NHS Trust - Charing Cross Hospital | London | |
United States | Lake Washington Vascular | Bellevue | Washington |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | OhioHealth Riverside Methodist Hospital | Columbus | Ohio |
United States | Vascular Care Connecticut | Darien | Connecticut |
United States | Valley Vascular Surgical Associates | Fresno | California |
United States | Orion Medical | Houston | Texas |
United States | Yale School of Medicine | New Haven | Connecticut |
United States | New York-Presbyterian Hospital/Weill Cornell Medical Center | New York | New York |
United States | Yavapai Regional Medical Center | Prescott Valley | Arizona |
United States | PIMA Heart and Vascular | Tucson | Arizona |
United States | Georgetown University Medical Center | Washington | District of Columbia |
United States | Vascular Care Group | Wellesley | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Medtronic Endovascular |
United States, Australia, Canada, France, Germany, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Venous treatment satisfaction questionnaire-early (VenousTSQe)(For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) | Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe). | 30 days | |
Primary | Venous treatment satisfaction questionnaire- status (VenousTSQs) (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) | Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs). | 30 days | |
Primary | Percentage of target vein treated (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study) | Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated. | Index procedure | |
Primary | Time to ulcer healing (For VLU study) | Time to ulcer healing, calculated through healing confirmation and verified by an independent core laboratory. | Index procedure through 12 months | |
Secondary | Anatomic closure of the primary target superficial truncal vein | Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures. | 6 months | |
Secondary | Time to return to work | Through study completion, an average of 30 days | ||
Secondary | Anatomic closure of primary target vein | Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures. | 30 days, and 12, 24, 36, 48 and 60 months (30 days and 12 months only for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Anatomic closure of target vein | Measured via Duplex Ultrasound showing target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures. | 30 days, and 6, 12, 24, 36, 48 and 60 months (30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Technical success of each target vein | Measured via Duplex Ultrasound showing target vein (including primary target vein) closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures. | Index procedure | |
Secondary | Reintervention of any target vein | Assessed via number of the target veins requiring retreatment. | Index procedure through 60 months (through 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Time to reintervention of any target vein | Index procedure through 60 months (through 12 months for VenaSeal vs. Surgical Stripping Study) | ||
Secondary | Adverse events (AEs) occurring in the target limb | Adverse events occurring in target limb, evaluated from index procedure through 12 months are hypersensitivity to VenaSeal™ adhesive, phlebitis, granuloma, endovenous glue induced thrombosis (EGIT) or endovenous heat induced thrombosis (EHIT), symptomatic deep vein thrombosis (DVT) events. | Index procedure through 12 months | |
Secondary | Additional adverse events | Additional adverse events that will be evaluated through 60 months are symptomatic pulmonary embolism (PE) and serious adverse events (SAEs). | Index procedure through 60 months (through 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Healthcare utilization measured by the number of each type of adjunctive treatment. | Index procedure through 12 months | ||
Secondary | Healthcare utilization measured by number of healthcare resources and other health related resources utilized for target limb venous reflux disease | Index procedure through 60 months (30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | ||
Secondary | Healthcare utilization measured by number of healthcare resources utilized for adverse events | Index procedure through 60 months (through 12 months for VenaSeal vs. Surgical Stripping Study) | ||
Secondary | For VLU study only: Healthcare utilization measured by number of ulcer related healthcare resources utilized | Index procedure through 60 months | ||
Secondary | Time to return to normal activities | Through study completion, an average of 30 days | ||
Secondary | Intra-procedural and post-procedural pain | Determined by using numeric rating scale (NRS) with a scale of 0-10, with '0' indicating no pain and '10' indicating worst pain imaginable. | Index procedure, and 7 days and 30 days | |
Secondary | Change in venous disease symptoms compared to baseline measured by the revised Venous Clinical Severity Score (rVCSS) | rVCSS score ranges from 0 to 30, with higher score indicating severe venous disease. | 7 and 30 days, and at 6, 12, 24, 36, 48, and 60 months (7 and 30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Change in venous disease symptoms compared to baseline as measured by subject self-reporting symptoms | 7 and 30 days, and at 6, 12, 24, 36, 48, and 60 months (7 and 30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | ||
Secondary | Change in Aberdeen Varicose Vein Questionnaire (AVVQ) score compared to baseline | The total score ranges from 0-100 points, with '0' point indicating the best quality of life and '100' points indicating worst quality of life. | 30 days, and 6, 12, 24, 36, 48, and 60 months (30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Change in EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L) compared to baseline | Items are scored on a 1-5 scale, 5 being a worse outcome. Each of the 5 dimensions are scored separately to obtain a 5-digit code which is converted into a standard value by country. Max & min values vary by country. | 30 days, and 6, 12, 24, 36, 48 and 60 months (30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Change in the 36-Item Short Form Health Survey (SF-36) compared to baseline | The total score ranges from 0 to 100, with higher scores indicating better general health perception. | 30 days, and 6 and 12 months | |
Secondary | Change in the Venous Dependent Quality of Life (VenousDQoL) compared to baseline | Measured by 0-5 and 0-7 point (there are two scales in this questionnaire) Likert scale with higher score indicating worst outcome. | 30 days, and 6, 12, 24, 36, 48, and 60 months (30 days, 6 and 12 months for VenaSeal vs. Surgical Stripping Study) | |
Secondary | Provider experience evaluating overall satisfaction with the procedure | Measured by a 5 point Likert scale ranging from 0-5, with 5 indicating the best outcome (extremely satisfied with the treatment). | Index procedure | |
Secondary | For VLU Study: Ulcer recurrence on the target limb | Following ulcer healing through 60 months | ||
Secondary | For VLU study: Ulcer healing rate | Index procedure through 24 months or until ulcer healing has been confirmed | ||
Secondary | For VLU Study: Ulcer-free time | Through 60 months | ||
Secondary | For VLU Study: Venous treatment satisfaction questionnaire-early (VenousTSQe) | Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe). | 30 days | |
Secondary | For VLU Study: Venous treatment satisfaction questionnaire- status (VenousTSQs) | Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs). | 30 days | |
Secondary | For VLU Study: Percentage of target vein treated | Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated. | Index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05504070 -
Venclose digiRF System Post Market Study
|
N/A | |
Recruiting |
NCT05633277 -
Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections
|
N/A | |
Completed |
NCT02553720 -
The ATLANTIS Trial
|
N/A | |
Completed |
NCT04758728 -
Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping
|
N/A | |
Withdrawn |
NCT02936271 -
Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting
|
N/A | |
Completed |
NCT02585726 -
Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)
|
N/A | |
Active, not recruiting |
NCT04339075 -
Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore
|
||
Recruiting |
NCT04146168 -
Lake Washington Vascular VenaSeal™ Post-Market Evaluation
|
||
Not yet recruiting |
NCT01901731 -
Pelvic Embolisation to Reduce Recurrent Varicose Veins - Primary
|
N/A | |
Completed |
NCT00509392 -
ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
|
Phase 4 | |
Not yet recruiting |
NCT04774939 -
EVLA and Optimal Timing of Sclerotherapy
|
N/A | |
Not yet recruiting |
NCT04339088 -
High Intensity Focused Ultrasound in PAtients With Varicose Veins in Singapore
|
||
Completed |
NCT04006184 -
Retrospective Review of Saphenous Vein Incompetence: Venaseal Versus Endovenous Thermal Ablation
|
||
Not yet recruiting |
NCT01909024 -
Pelvic Embolisation to Reduce Recurrent Varicose Veins - Recurrent
|
N/A | |
Recruiting |
NCT03250247 -
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
|
N/A | |
Active, not recruiting |
NCT05707169 -
Comparison of Zero- and Two-centimeter Distance From Sapheno-femoral Junction in Laser Ablation of Varicose Vein
|
N/A | |
Recruiting |
NCT04384315 -
Efficacy and Safety of Endovenous Radio Frequency (EVRF) for Treatment of Varicose Veins in Singapore
|
||
Completed |
NCT01549860 -
Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers
|
N/A | |
Completed |
NCT00842296 -
ClosureFAST - Radiofrequency Great Saphenous Vein Treatment
|
N/A | |
Completed |
NCT03893201 -
A Singapore Venaseal Real World Post-Market Evaluation Study
|